Histamine receptors as potential therapeutic targets to treat anxiety and depression

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Increasing evidence supports a role for histamine in anxiety and depression. In most studies, histamine and stimulation of the histamine H 1 receptor (H1R) or blockade of the histamine H 2 receptor (H2R) increase measures of anxiety. In contrast, in most studies histamine reduces depression-like activity, which might be related to effects of histamine on waking. These effects of histamine on anxiety and depression make histamine receptor ligands attractive therapeutic targets. As most studies assessing the potential of histamine receptor ligands on depression did not exclude potential effects of these ligands on locomotor activity, more studies are warranted to determine the exact role of histamine receptor subtypes in depression. The effects of histamine-mediated signaling on anxiety and depression should also be considered in assessments of the potential of histamine H3 receptor (H3R) ligands for conditions characterized by cognitive impairments as well as noncognitive behavioral impairments.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalDrug Development Research
Volume65
Issue number3
DOIs
StatePublished - Jul 2005

Fingerprint

Histamine Receptors
Histamine
Anxiety
Depression
Ligands
Therapeutics
Histamine H3 Receptors
Locomotion

Keywords

  • Arginine vasopressin
  • Corticotropin-releasing hormone
  • Elevated plus maze
  • Elevated zero maze
  • Hypothalamic-pituitary-adrenal axis

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Histamine receptors as potential therapeutic targets to treat anxiety and depression. / Raber, Jacob.

In: Drug Development Research, Vol. 65, No. 3, 07.2005, p. 126-132.

Research output: Contribution to journalArticle

@article{50abeb67e7d842fbbec3a83fb9d08195,
title = "Histamine receptors as potential therapeutic targets to treat anxiety and depression",
abstract = "Increasing evidence supports a role for histamine in anxiety and depression. In most studies, histamine and stimulation of the histamine H 1 receptor (H1R) or blockade of the histamine H 2 receptor (H2R) increase measures of anxiety. In contrast, in most studies histamine reduces depression-like activity, which might be related to effects of histamine on waking. These effects of histamine on anxiety and depression make histamine receptor ligands attractive therapeutic targets. As most studies assessing the potential of histamine receptor ligands on depression did not exclude potential effects of these ligands on locomotor activity, more studies are warranted to determine the exact role of histamine receptor subtypes in depression. The effects of histamine-mediated signaling on anxiety and depression should also be considered in assessments of the potential of histamine H3 receptor (H3R) ligands for conditions characterized by cognitive impairments as well as noncognitive behavioral impairments.",
keywords = "Arginine vasopressin, Corticotropin-releasing hormone, Elevated plus maze, Elevated zero maze, Hypothalamic-pituitary-adrenal axis",
author = "Jacob Raber",
year = "2005",
month = "7",
doi = "10.1002/ddr.20015",
language = "English (US)",
volume = "65",
pages = "126--132",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Histamine receptors as potential therapeutic targets to treat anxiety and depression

AU - Raber, Jacob

PY - 2005/7

Y1 - 2005/7

N2 - Increasing evidence supports a role for histamine in anxiety and depression. In most studies, histamine and stimulation of the histamine H 1 receptor (H1R) or blockade of the histamine H 2 receptor (H2R) increase measures of anxiety. In contrast, in most studies histamine reduces depression-like activity, which might be related to effects of histamine on waking. These effects of histamine on anxiety and depression make histamine receptor ligands attractive therapeutic targets. As most studies assessing the potential of histamine receptor ligands on depression did not exclude potential effects of these ligands on locomotor activity, more studies are warranted to determine the exact role of histamine receptor subtypes in depression. The effects of histamine-mediated signaling on anxiety and depression should also be considered in assessments of the potential of histamine H3 receptor (H3R) ligands for conditions characterized by cognitive impairments as well as noncognitive behavioral impairments.

AB - Increasing evidence supports a role for histamine in anxiety and depression. In most studies, histamine and stimulation of the histamine H 1 receptor (H1R) or blockade of the histamine H 2 receptor (H2R) increase measures of anxiety. In contrast, in most studies histamine reduces depression-like activity, which might be related to effects of histamine on waking. These effects of histamine on anxiety and depression make histamine receptor ligands attractive therapeutic targets. As most studies assessing the potential of histamine receptor ligands on depression did not exclude potential effects of these ligands on locomotor activity, more studies are warranted to determine the exact role of histamine receptor subtypes in depression. The effects of histamine-mediated signaling on anxiety and depression should also be considered in assessments of the potential of histamine H3 receptor (H3R) ligands for conditions characterized by cognitive impairments as well as noncognitive behavioral impairments.

KW - Arginine vasopressin

KW - Corticotropin-releasing hormone

KW - Elevated plus maze

KW - Elevated zero maze

KW - Hypothalamic-pituitary-adrenal axis

UR - http://www.scopus.com/inward/record.url?scp=28444440221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444440221&partnerID=8YFLogxK

U2 - 10.1002/ddr.20015

DO - 10.1002/ddr.20015

M3 - Article

AN - SCOPUS:28444440221

VL - 65

SP - 126

EP - 132

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 3

ER -